Novo said the trials, which enrolled nearly 4,000 patients, did not “translate into a delay of disease progression” even as it “resulted in improvement of Alzheimer’s disease-related biomarkers”. Well, in an update to staff in June, Amazon chief executive Andy Jassy stated the company would reduce jobs in some areas while it hired in others. Novo’s troubles have led to the ousting of Lars Fruergaard Jørgensen as chief executive in May. Former Novo chief executive Lars Rebien Sorensen was appointed chair of its board in October, after the previous chair and six other directors stood down. More data from the Alzheimer’s trials will be presented at a scientific conference next month with full data expected next year.
